Endocrine Abstracts

Background: Recent studies suggest that metformin (MF) may reduce TSH concentration. This fact could imply a dosage reduction of levothyroxine among those hypothyroid patients taking metformin.Aim: To determine, in a retrospective analysis, the impact of metformin in thyroidectomized patients (a condition not influenced by endogenous thyroid hormone production) on levothyroxine replacement.Patients and methods: One hundred ninety t...

One of the most important activating genetic aberrations in differentiated thyroid cancer (DTC) development pathways involves the RET/PTC–RAS–RAF–MAPK axis. Mutations in the RET gene are essential in medullary thyroid carcinoma (MTC). Sorafenib is the first compound to reach clinical practice that is capable of inhibiting all the RAF kinases. Moreover, it targets a panel of tyrosine kinase receptors, such as VEGF receptors which gives to sorafenib not only proap...

Aim: Investigate, in patients with differentiated thyroid cancer (DTC) if thyroglobulin (Tg) values, immediately before and six months post radioiodine ablation are good predictors of disease progression.Materials and methods: Basal Tg values (Tg-B) and rhTSH stimulated Tg (Tg-S) before ablation (0) and 6 months later (6) from 142 DTC patients, with post-surgical ablation therapy between 2003 and 2009 with a follow up of 5 years, were analysed.<p cla...

In PTC, radioiodine required dose for thyroid remnant ablation is uncertain. Recent works show that low doses may be sufficient for low risk patients.Aim: To evaluate the efficacy and safety of thyroid remnant ablation in patients with low-risk PTC by using 1100 MBq (30 mCi) outpatient doses.Materials and methods: Twenty-five patients (24 women, 55 years-old mean age, range 34–77) referred for ablation of postsurgical thyroid ...

Background and aim: Papillary thyroid carcinomas (PTCs) with a diameter <1 cm are referred to as papillary microcarcinomas (PTMCs). They are being diagnosed with increasing frequency. Within this type of tumour some clinical and histological characteristics with prognostic and therapeutic impact have been proposed. In the present study we describe the clinical and pathological presentation of PTMCs and compare them with papillary thyroid carcinomas of larger size.<p cl...

IntroductionMultifocality is a common finding in papillary thyroid carcinoma (PTC), but its biological significance is not well established. In some cases not all foci present the same histological pattern.ObjectiveTo study the different histological patterns and molecular profiles of multifocal PTC (mPTC).Material and methodsAll patients with a confirmed diagnosi...

Introduction: Classically, risk stratification in papillary thyroid carcinoma (PTC) assigned the same magnitude of risk to all patients with regional lymph node involvement (N1 disease). However, specific lymph node characteristics (such as size, number, extension, etc.) will allow individualizing treatment and follow-up. One-Step Nucleic Acid Amplification (OSNA) measures the number of copies of mRNA of cytokeratin 19 (CK19) as a marker of lymph node metastasis. Thus, copy nu...

Background: 131I-norcholesterol scintigraphy (INCS) is currently not considered a main confirmatory and localizing study in primary aldosteronism (PA), however few recent data is available. On the other hand, adrenal venous sampling (AVS) is technically difficult, and may also lead to erroneuos diagnosis.Aim: To describe the performance of INCS, done under dexamethasone (DXM) supression, in daily practice.Patients and methods: Retr...

Introduction: Most thyroid cancer (TC) patients have a good prognosis, but some of them show aggressive behavior and are resistant to treatment. Still no effective biomarkers are available to predict which patients will progress. Epigenetic alterations are a hallmark of cancer, and profiling DNA methylation has allowed a better understanding of the epigenetic landscape of TC and its influence in TC progression. However, bulk DNA methylomes include information not only from tum...

Response to therapy re-stratification approach has been recently included in the 2015 ATA guidelines as a risk-adapted approach to management of thyroid cancer. Our aim was to investigate the clinical utility of response to therapy variables obtained during early follow-up in combination with BRAF, a prominent oncogene in thyroid cancer with prognostic value. This was a retrospective multicenter study of 871 patients at 11 centers in Spain with papillary thyroid cancer followe...